Open access · CC-BY
via OpenAlex
Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
James B. Koprich, Tom H. Johnston, Philippe Huot, M. Gabriela Reyes, Maria Carmen Espinosa, Jonathan M. Brotchie
PLoS ONE · 2011 · ▲ 111 citations
Abstract
The pathological hallmarks of Parkinson's disease (PD) are degeneration of dopamine (DA) neurons of the substantia nigra (SN) and the presence of alpha-synuclein (α-syn)-rich Lewy bodies in DA cells that remain. To model these aspects of the disease, we previously showed that high titer (5.1×10exp12 gp/ml) AAV1/2 driven expression of A53T α-syn in the SN of rats caused nigrostriatal pathology including a loss of DA neurons, but also with toxicity in the GFP control group. In the current study, we evaluate the effects of two lower titers by dilution of the vector (1∶3 [1.7×10exp12] and 1∶10 [5.1×10exp11]) to define a concentration that produced pathology specific for α-syn. In GFP and empty vector groups there were no behavioural or post-mortem changes at 3 or 6 weeks post-administration at either vector dose. Dilution of the AAV1/2 A53T α-syn (1:3) produced significant paw use asymmetry, reductions in striatal tyrosine hydroxylase (TH), and increases in DA turnover at 3 weeks in the absence of overt pathology. By 6 weeks greater evidence of pathology was observed and included, reductions in SN DA neurons, striatal DA, TH and DA-transporter, along with a sustained behavioural deficit. In contrast, the 1:10 AAV1/2 A53T α-syn treated animals showed normalization between 3 and 6 weeks in paw use asymmetry, reductions in striatal TH, and increased DA turnover. Progression of dopaminergic deficits using the 1:3 titer of AAV1/2 A53Tα-syn provides a platform for evaluating treatments directed at preventing and/or reversing synucleinopathy. Use of the 1:10 titer of AAV1/2 A53T α-syn provides an opportunity to study mechanisms of endogenous compensation. Furthermore, these data highlight the need to characterize the titer of vector being utilized, when using AAV to express pathogenic proteins and model disease process, to avoid producing non-specific effects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1371/journal.pone.0017698
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Koprich, J.B., Johnston, T.H., Huot, P., Reyes, M.G., Espinosa, M.C., & Brotchie, J.M. (2011). Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein. <em>PLoS ONE</em>. https://doi.org/10.1371/journal.pone.0017698
Vancouver
Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa MC, Brotchie JM. Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein. PLoS ONE. 2011. doi:10.1371/journal.pone.0017698.
BibTeX
@article{james2011Progre,
title = {Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein},
author = {James B. Koprich and Tom H. Johnston and Philippe Huot and M. Gabriela Reyes and Maria Carmen Espinosa and Jonathan M. Brotchie},
journal = {PLoS ONE},
year = {2011},
doi = {10.1371/journal.pone.0017698},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Parkinson s Disease 2016
Open access · CC-BY
Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Gastroenterology Research and Practice 2015
Open access · CC-BY
Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson’s Disease
Brain 2005
Open access · OA
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease
Journal of the Neurological Sciences 2023
Open access · CC-BY
Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease
Experimental Neurobiology 2015
Open access · OA
Mitochondrial Dysfunction in Parkinson’s Disease
Biomolecules 2021
Open access · CC-BY